Adcock puts off vote on CFR buyout again; J&J petitions FDA on biosim names; GW wins French OK for Sativex;

@FiercePharma: Mallinckrodt Pharmaceuticals and Zogenix to End Co-Promotion Agreement. Release | Follow @FiercePharma

@TracyStaton: Most popular special report FiercePharma today: Top 10 Drug Patent Losses of 2014. Report | Follow @TracyStaton

@EricPFierce: Let us satisfy your app..etite for FiercePharma news. iOS folks here; Android here. | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: J&J's Imbruvica bests GSK's Arzerra in CLL trial, raising hopes for off-label sales. Story | Follow @CarlyHFierce

> South African drugmaker Adcock Ingram, up for sale, has once again delayed a shareholder vote on a $1.2 billion takeover offer from Chile's CFR Pharmaceuticals. Report

> Johnson & Johnson ($JNJ) submitted a citizen petition to the FDA, asking the agency to require biosimilar drugs to be named similarly to their reference products, but not identically. Report

> French health authorities approved GW Pharmaceuticals' cannabis-based drug, Sativex, to treat muscle spasms associated with multiple sclerosis. Report

> Some over-the-counter laxatives containing sodium phosphate can be dangerous if used too often, the FDA said. Report

> Amneal Pharmaceuticals tapped former Warner Chilcott SVP Rochelle Fuhrmann as its CFO. Report

Medical Device News

@FierceMedDev: Avelas Biosciences closes $6.85M Series B for real-time cancer visualization tech. Release | Follow @FierceMedDev

@MichaelGFierce: Hot on FierceDrugDelivery this week: How a single nanoparticle delivers two drugs separately to kill cancer cells. Story | Follow @MichaelGFierce

@EmilyWFierce: FiercePharma has gone mobile! Check out the new app here. | Follow @EmilyWFierce

@MarkHFierce: Sorin knows: a local device development partner in China is good way to boost its market presence there. Story | Follow @MarkHFierce

> Medtronic's flunked trial throws its hypertension program into doubt. Story

> Facing a Dx sales slump, Quest taps Illumina, Life Tech and UCSF for R&D. More

> Covidien, NEA and Lightstone are backing a stealthy Irish med tech startup. News

> Lombard plots a U.S. IPO as aortic aneurysm device takes off. Article

Biotech News

@FierceBiotech: Intercept halts FLINT trial early after meeting endpoint in nonalcoholic steatohepatitis. Release | Follow @FierceBiotech

@JohnCFierce: Oh, man. Intercept up to $255 - or +250%. Market cap now just under $5B. | Follow @JohnCFierce

@DamianFierce: Zymeworks pockets $15M, woos Eli Lilly with its double-barreled antibodies. Story | Follow @DamianFierce

@EmilyMFierce: ICYMI: Embryonic-like stem cells created from frozen tissue of Alzheimer's patients. Story from FierceBiotech Research | Follow @EmilyMFierce

> One of biotech's top R&D chiefs makes the leap to the VC crowd at NEA. Story

> Biogen Idec forges a $320M gene editing deal aimed at curing inherited blood disorders. News

> Intercept shares dazzle after early success of PhIIb liver disease drug trial. More

> Pfizer outsources PhIII Bosulif study to upstart Avillion. Item

Pharma Manufacturing News

> McKesson's new offer appeases hedge fund on Celesio buyout. Story

> FDA names Sklamberg to oversee global regulatory issues. Item

> Roche's Genentech tells the FDA to expect a brief Tamiflu shortage. Article

> Patheon's deal for DSM would transform it into the 2nd largest CMO in the world. News

> Amgen facility has its 2nd explosion in 9 months. More

> Rumored Novartis, Merck asset swap has interesting manufacturing implications. Report

Vaccines News

> Astellas inks deal to create a portfolio of vaccine-focused biotechs. Story

> H1N1 deaths drive a surge in demand for flu vaccine. Report

> China gives hep B vaccine a clean bill of health but suspicions remain. News

> Study finds giving Prevnar and flu vaccine together raises risk of fever. More

> Students in California are still waiting for Novartis' Bexsero to arrive. Article

> Protein Sciences calls on Connecticut to buy its flu vaccine. Item

And Finally... Canada's health minister said a person died in Alberta this week of the H5N1 flu virus; officials called it an "isolated case." Report (sub. req.)

Suggested Articles

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

BMS executives pointed to upcoming Opdivo data releases, as well as strong demand for other drugs in the portfolio, as reasons for optimism.

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back.